Copyright
©The Author(s) 2016.
World J Cardiol. Oct 26, 2016; 8(10): 615-622
Published online Oct 26, 2016. doi: 10.4330/wjc.v8.i10.615
Published online Oct 26, 2016. doi: 10.4330/wjc.v8.i10.615
Table 3 Baseline medications and clinical presentation in the control group and remote ischemic preconditioning group
| Characteristic | Control (n = 51) | RIPC (n = 51) | P |
| Medications % (n) | |||
| Alpha blockers | 7.8 (4) | 2.0 (1) | 0.36 |
| Beta blockers | 78.4 (40) | 80.4 (41) | 1.00 |
| ACE-inhibitors | 37.3 (19) | 41.2 (21) | 0.84 |
| Aspirin | 90.2 (46) | 90.2 (46) | 1.00 |
| Statins | 84.3 (43) | 86.3 (44) | 1.00 |
| Clinical presentation % (n) | |||
| Stable angina | 23.5 (12) | 23.5 (12) | 1.00 |
| Unstable angina | 25.5 (13) | 25.5 (13) | 1.00 |
| Positive stress test | 27.5 (14) | 25.5 (13) | 1.00 |
| Non-STEMI | 19.6 (10) | 17.6 (9) | 1.00 |
| STEMI | 0.0 (0) | 2.0 (1) | 1.00 |
| Valve without CAD | 17.6 (9) | 27.5 (14) | 0.34 |
- Citation: Lotfi AS, Eftekhari H, Atreya AR, Kashikar A, Sivalingam SK, Giannoni M, Visintainer P, Engelman D. Randomized controlled trial of remote ischemic preconditioning and atrial fibrillation in patients undergoing cardiac surgery. World J Cardiol 2016; 8(10): 615-622
- URL: https://www.wjgnet.com/1949-8462/full/v8/i10/615.htm
- DOI: https://dx.doi.org/10.4330/wjc.v8.i10.615